Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Provided By GlobeNewswire
Last update: Dec 17, 2024
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
Read more at globenewswire.com2.82
+0.11 (+4.06%)
Find more stocks in the Stock Screener
CYCN Latest News and Analysis
19 days ago - ChartmillTop movers in Monday's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
19 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
19 days ago - ChartmillKeep an eye on the top gainers and losers in Monday's session.Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
